Evidence map›Paper›PMID 25544859›Full record

ArticleExpert review of ophthalmology2014

Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.

Fatemeh Rajaii, Allison N McCoy, Terry J Smith

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fatemeh Rajaii *Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105.
Allison N McCoy *Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105.
Terry J SmithDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105.
University of Michigan–Ann Arbor · US

Funding

ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ANDERSON, GAIL V · 1985 to 2011
$74.2M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
REGULATION OF RETROOCULAR CONNECTIVE TISSUER01EY008976 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 1993 to 2020
$6.4M
FUNCTIONAL DIVERSITY OF ORBITAL FIBROBLASTSR01EY011708 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 1997 to 2011
$4.3M
Immunoglobulin Activation of FibroblastsR01DK063121 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 2004 to 2012
$3.2M
E75 IN THE DEVELOPING DROSOPHILA EYEF31EY007003 · NEI · YALE UNIVERSITY · PI SHILTON, ALYCIA N · 1999 to 2001
$14k
NCRR NIH HHS M01 RR000425NEI NIH HHS F31 EY007003NEI NIH HHS P30 EY007003NEI NIH HHS R01 EY008976NEI NIH HHS R01 EY011708NIDDK NIH HHS R01 DK063121
6 · The paper itself

Abstract

The pathophysiology underlying Graves' disease and its ocular manifestation, thyroid associated ophthalmopathy (TAO) is incompletely understood. Characterization of the mononuclear cells driving the disease and the cytokines they produce has led to significant advances in our understanding of TAO. This in turn has resulted in the identification of potentially attractive drug targets. For instance, development of inhibitors of specific cytokine pathways for use in other autoimmune diseases now presents an opportunity for their application in TAO. In this paper, we review the rationale for considering anti-cytokine therapy in TAO, evidence linking specific cytokines such as interleukin-6, tumor necrosis factor-α, and interleukin-17 pathways to TAO, and explore the potential for targeting of these pathways as therapy.

Indexed as

autoimmunitycytokinesCytokinesGraves’ diseaseGraves’ orbitopathyinflammationinterleukinsthyroid-associated ophthalmopathy

Identifiers

PMID25544859
PMCPMC4275044
OpenAlexW2145926290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.